SGLT2 Inhibitors Treatment Market Segmentation:
Indication Segment Analysis
Based on the indication type 2 diabetes segment is projected to garner the largest revenue share of 68.6% in the SGLT2 inhibitors treatment market during the forecast period. The growing disease burden and the notable benefits demonstrated by these SGLT2 inhibitors make the subtype dominant in this sector. As per a DRWF article published in April 2025 Horizon Europe programme dedicated a total of €6.99 million is a large-scale, seven-year clinical trial evaluating the long-term effects of dapagliflozin on cardiovascular and kidney health in over 3,000 high-risk hypertension patients across 53 centres in Europe. This continuous research further strengthens their position in this field.
Distribution Channel Segment Analysis
In terms of distribution channel hospital pharmacies segment is expected to attain a significant share of 60.5% in the SGLT2 inhibitors treatment market during the discussed time frame. The ability of these settings to deliver specialty care and manage high-risk patients allows them to secure higher capital influx through most prescriptions. The NIH study in June 2022 observed that a survey of 348 community pharmacists revealed moderate knowledge about SGLT2 inhibitors, with about one-third aware of their blood pressure-lowering effects and proper patient counseling. Besides, nearly half reported receiving 1 to 5 prescriptions monthly, with patients generally giving positive feedback, hence a wider segment scope.
Drug Segment Analysis
Based on the drug, the empagliflozin segment is expected to grow at a considerable rate, with a share of 52.7% in the SGLT2 inhibitors treatment market by the end of 2035. The growth in the segment originates from efficacious cardiovascular and renal outcomes offered in treating CKD. As per a May 2023 NIH article, the subtype displays efficacy in glycemic control backed by the landmark EMPA-REG OUTCOME trial, which was the first SGLT2 inhibitor approved to reduce cardiovascular death, boosting its clinical value and market adoption. The study further stated that its utility as monotherapy or in fixed-dose combinations enhances patient adherence, hence allowing greater market penetration.
Our in-depth analysis of the SGLT2 inhibitors treatment market includes the following segments:
|
Segment |
Subsegments |
|
Indication |
|
|
Distribution Channel |
|
|
Drug |
|
